Deciphera Pharms Drug Patent Portfolio

Deciphera Pharms owns 1 orange book drug protected by 36 US patents Given below is the list of Deciphera Pharms's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11779572 Methods of treating gastrointestinal stromal tumors 06 Oct, 2042
Active
US11969414 Methods of treating gastrointestinal stromal tumors 08 Feb, 2041
Active
US11185535 Amorphous kinase inhibitor formulations and methods of use thereof 30 Dec, 2040
Active
US11395818 Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea 30 Dec, 2040
Active
US11576903 Amorphous kinase inhibitor formulations and methods of use thereof 30 Dec, 2040
Active
US11612591 Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea 30 Dec, 2040
Active
US11793795 Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea 30 Dec, 2040
Active
US11801237 Amorphous kinase inhibitor formulations and methods of use thereof 30 Dec, 2040
Active
US11844788 Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea 30 Dec, 2040
Active
US11850240 Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea 30 Dec, 2040
Active
US11850241 Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea 30 Dec, 2040
Active
US11896585 Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea 30 Dec, 2040
Active
US11903933 Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea 30 Dec, 2040
Active
US11911370 Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea 30 Dec, 2040
Active
US11918564 Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea 30 Dec, 2040
Active
US11969415 (methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea 30 Dec, 2040
Active
US12023328 Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea 30 Dec, 2040
Active
US12064422 Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea 30 Dec, 2040
Active
US10966966 Methods of treating gastrointestinal stromal tumors 12 Aug, 2040
Active
US11266635 Methods of treating gastrointestinal stromal tumors 12 Aug, 2040
Active
US11344536 Methods of treating gastrointestinal stromal tumors 12 Aug, 2040
Active
US11426390 Methods of treating gastrointestinal stromal tumors 12 Aug, 2040
Active
US11433056 Methods of treating gastrointestinal stromal tumors 12 Aug, 2040
Active
US11529336 Methods of treating gastrointestinal stromal tumors 12 Aug, 2040
Active
US11534432 Methods of treating gastrointestinal stromal tumors 12 Aug, 2040
Active
US11576904 Methods of treating gastrointestinal stromal tumors 12 Aug, 2040
Active
US11813251 Methods of treating gastrointestinal stromal tumors 12 Aug, 2040
Active
US12023325 Methods of treating gastrointestinal stromal tumors 12 Aug, 2040
Active
US12023326 Methods of treating gastrointestinal stromal tumors 12 Aug, 2040
Active
US12023327 Methods of treating gastrointestinal stromal tumors 12 Aug, 2040
Active
US12059410 Methods of treating gastrointestinal stromal tumors 12 Aug, 2040
Active
US12059411 Methods of treating gastrointestinal stromal tumors 12 Aug, 2040
Active
US8461179 Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases 15 May, 2034
Active
US8940756 Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases 07 Jun, 2032
Active
USRE48731 Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases 07 Jun, 2032
Active
US8188113 Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases 27 Jul, 2030
Active


Given below is the list of recent legal activities going on the following drug patents of Deciphera Pharms.

Activity Date Patent Number
Patent litigations
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 03 Jul, 2024 US11918564
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 03 Jul, 2024 US11779572
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 03 Jul, 2024 US11850241
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 03 Jul, 2024 US11911370
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 03 Jul, 2024 US11969415
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 03 Jul, 2024 US11969414
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 03 Jul, 2024 US11844788
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 03 Jul, 2024 US11850240
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 03 Jul, 2024 US11896585
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 03 Jul, 2024 US11903933
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 03 Jul, 2024 US11813251
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 03 Jul, 2024 US11793795
Entity Status Set To Undiscounted (Initial Default Setting or Status Change) 03 Jul, 2024 US11801237
Electronic Review 07 Jun, 2024 US11969414
Email Notification 30 Apr, 2024 US11969414


Deciphera Pharms's Family Patents

Deciphera Pharms drugs have patent protection in a total of 13 countries. It's US patent count contributes only to 44.7% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree.

Family Patents



Deciphera Pharms Drug List

Given below is the complete list of Deciphera Pharms's drugs and the patents protecting them.


1. Qinlock

Qinlock is protected by 36 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11779572 Methods of treating gastrointestinal stromal tumors 06 Oct, 2042
(18 years from now)
Active
US11969414 Methods of treating gastrointestinal stromal tumors 08 Feb, 2041
(16 years from now)
Active
US11185535 Amorphous kinase inhibitor formulations and methods of use thereof 30 Dec, 2040
(16 years from now)
Active
US11395818 Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea 30 Dec, 2040
(16 years from now)
Active
US11576903 Amorphous kinase inhibitor formulations and methods of use thereof 30 Dec, 2040
(16 years from now)
Active
US11612591 Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea 30 Dec, 2040
(16 years from now)
Active
US11793795 Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea 30 Dec, 2040
(16 years from now)
Active
US11801237 Amorphous kinase inhibitor formulations and methods of use thereof 30 Dec, 2040
(16 years from now)
Active
US11844788 Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea 30 Dec, 2040
(16 years from now)
Active
US11850240 Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea 30 Dec, 2040
(16 years from now)
Active
US11850241 Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea 30 Dec, 2040
(16 years from now)
Active
US11896585 Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea 30 Dec, 2040
(16 years from now)
Active
US11903933 Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea 30 Dec, 2040
(16 years from now)
Active
US11911370 Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea 30 Dec, 2040
(16 years from now)
Active
US11918564 Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea 30 Dec, 2040
(16 years from now)
Active
US11969415 (methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea 30 Dec, 2040
(16 years from now)
Active
US12023328 Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea 30 Dec, 2040
(16 years from now)
Active
US12064422 Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea 30 Dec, 2040
(16 years from now)
Active
US10966966 Methods of treating gastrointestinal stromal tumors 12 Aug, 2040
(15 years from now)
Active
US11266635 Methods of treating gastrointestinal stromal tumors 12 Aug, 2040
(15 years from now)
Active
US11344536 Methods of treating gastrointestinal stromal tumors 12 Aug, 2040
(15 years from now)
Active
US11426390 Methods of treating gastrointestinal stromal tumors 12 Aug, 2040
(15 years from now)
Active
US11433056 Methods of treating gastrointestinal stromal tumors 12 Aug, 2040
(15 years from now)
Active
US11529336 Methods of treating gastrointestinal stromal tumors 12 Aug, 2040
(15 years from now)
Active
US11534432 Methods of treating gastrointestinal stromal tumors 12 Aug, 2040
(15 years from now)
Active
US11576904 Methods of treating gastrointestinal stromal tumors 12 Aug, 2040
(15 years from now)
Active
US11813251 Methods of treating gastrointestinal stromal tumors 12 Aug, 2040
(15 years from now)
Active
US12023325 Methods of treating gastrointestinal stromal tumors 12 Aug, 2040
(15 years from now)
Active
US12023326 Methods of treating gastrointestinal stromal tumors 12 Aug, 2040
(15 years from now)
Active
US12023327 Methods of treating gastrointestinal stromal tumors 12 Aug, 2040
(15 years from now)
Active
US12059410 Methods of treating gastrointestinal stromal tumors 12 Aug, 2040
(15 years from now)
Active
US12059411 Methods of treating gastrointestinal stromal tumors 12 Aug, 2040
(15 years from now)
Active
US8461179 Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases 15 May, 2034
(9 years from now)
Active
US8940756 Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases 07 Jun, 2032
(7 years from now)
Active
USRE48731 Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases 07 Jun, 2032
(7 years from now)
Active
US8188113 Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases 27 Jul, 2030
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Qinlock's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List